Europe's pharmaceuticals industry said on Tuesday (1 September) it had filed a complaint with the European Commission against a French law promoting the use of Roche's cancer drug Avastin as an alternative to more expensive eye treatments.
Modern pharmaceuticals are no longer exclusively produced in a chemicals laboratory, but are often developed using live cells. In Germany, such biopharmaceuticals are being sold and prescribed at an ever increasing rate – despite widespread scepticism over GMOs in Germany. EurActiv Germany reports .
A recent European comparison shows Germany’s expenditures on pharmaceuticals are above average. No other country offers medications for treating illnesses “as quickly and comprehensively” as the Federal Republic. EurActiv Germany reports.
Paracetamol tablets are the world’s most commonly used painkillers. According to a recent study published in the British journal Annals of the Rheumatic Diseases , prolonged use of the drug can have very harmful side effects. EurActiv France reports .
The EU is not going to change its food safety legislation under the negotiation for the Transatlantic Trade and Investment Partnership (TTIP), which means that GMOs can be marketed in the EU only once they have been authorised, and beef from the USA would be marketable in Europe only if it is hormone free, Ignacio Garcia Bercero of the European Commission told EurActiv Czech Republic.
Pharmaceutical drugs, and medical technology, will remain under the department of health (DG Sanco) in the next Commission, Jean-Claude Juncker, the President-elect, confirmed on Wednesday (22 October).
Jean-Claude Juncker has ceded to pressure from MEPs and abandoned his plan to return control of medicines and pharmaceutical products to the Industry Commissioner. This responsibility will instead remain in the hands of the Health Commissioner, EurActiv France reports .
Europe’s pharmaceutical industry has said it did not lobby for medicines and medical devices to be moved from the European Commission's health directorate (DG Sanco) to the enterprise directorate (DG Enterprise).
The German government initiated plans on Monday (15 September) to strengthen the country’s attractiveness for pharmaceutical research and development, but the Left Party warns it is likely to become an "image campaign" for pharmaceutical giants. EurActiv.de reports .
A new EU regulation is meant to make clinical trials easier and more transparent, a pivotal tool in the fight against deadly diseases like cancer. But researchers in Germany warn that the country may lose its role as a leader in international medicine. EurActiv Germany reports.
José Antonio Bastos, head of doctors without borders ( MSF ) in Spain , has spoken out against big pharmaceutical companies that "only think in terms of profit" and pay little attention to "real health needs" of the population in developing countries, EurActiv Spain reports.
The pharmaceutical industry is trying to 'mobilise' patient groups into lobbying against EU plans that will force companies to publish data from their clinical trials, according to an e-mail seen by a British newspaper.
The European Parliament, in agreement with EU member states, has added 12 new substances to the EU priority list of pollutants known to pose a risk to surface water. For the first time, three pharmaceuticals will also be included on a "watch list" of emerging pollutants that could one day be added to the priority list.
European regulators will clamp down on "pay-for-delay" deals in the pharmaceutical sector this month, fining Denmark's Lundbeck and eight other generic drug manufacturers for limiting access of cheaper products to the market.
SPECIAL REPORT / Rising drug costs and supply uncertainty threaten efforts to achieve universal immunisation after decades of steady progress in vaccinating African infants against crippling and deadly diseases, health workers say.
The OECD is urging its member governments to harmonise their clinical trial approval processes, citing a decline in the pharmaceutical sector in the EU, where the number of applications for clinical trials fell 25% between 2007 and 2011.
More transparency on the pricing and reimbursement of medicines should be the rule for the future to improve patient's access to affordable treatments, MEPs said after backing draft legislation in the environment and public health committee.